5/27 Taiwan Life Sciences Biweekly Newsletter
2024-05-27 |
| Taiwan Life Sciences Biweekly |
| Kinpo Group signs MOU with Taichung Veterans General Hospital for smart healthcare collaboration 22 May, 2024 Kinpo Group recently held a memorandum of understanding (MOU) signing ceremony with Taichung Veterans General Hospital, with the future collaboration between the two parties to involve developing telemedicine services, remote patient monitoring, smart operating rooms, intelligent command centers, AI healthcare, precision medicine, regenerative medicine, and advanced medical equipment. More... (in Chinese) |
| NARI to install cyclotron to stabilize local supply 20 May, 2024 The National Atomic Research Institute (NARI) is preparing to install a 70 million electron volts (MeV) cyclotron to produce short-half-life radiopharmaceuticals, which would stabilize the domestic supply of medical isotopes. The machine is scheduled to be completed in 2026 and begin producing radiopharmaceuticals in 2027, the institute said yesterday. Taiwan has to import most of its short-half-life radiopharmaceuticals from other countries, NARI vice president Wang Jeng-jong said. More... |
| Advanced Genomics APAC Collaborates with Genomics to Expand Asia-Pacific Cancer Early Screening Market Press release 17 May, 2024 Advanced Genomics APAC Co., Ltd. has forged a strategic partnership with Genomics BioSci & Tech Co., Ltd. to drive cancer early screening initiatives across the Asia-Pacific region, including Japan. This collaboration, announced upon the signing of the memorandum of understanding, represents a significant milestone in Advanced Genomics APAC's mission to meet the escalating demand for genetic testing services in the region with its innovative testing solutions. More... |
| Xi Yue Biomedicine plans for allogeneic cell clinical trial for cerebral palsy, IPO for end of 2024 16 May, 2024 Regenerative medicine company Xi Yue Biomedicine (formerly Guang Li Biomedicine) announced that it will submit an application to the Taiwan Food and Drug Administration (TFDA) for a Phase I/II clinical trial using allogeneic umbilical cord stem cells for the treatment of cerebral palsy. The company also announced that it will conduct an initial public offering (IPO) by the end of the year. More... (in Chinese) |
| Where Business and Breakthroughs Converge! Shaping the future of biotechnology with Taiwan at BIO 2024 16 May, 2024 The 2024 Convention will be held in person June 3-6, with more than 3,000 international and domestic companies in attendance at the San Diego Convention Center. The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) and Taiwan External Trade Development Council (TAITRA) are organizing a Taiwan Pavilion to showcase Taiwan's exceptional biotechnology and medical R&D capabilities. More... |
| If Korea, which has advanced biotechnology, and Taiwan, which has large-scale clinical data on stem cell and gene therapy, work together, it will create great synergy: Wang 16 May, 2024 "If Korea, which has advanced biotechnology, and Taiwan, which has large-scale clinical data on stem cell and gene therapy, work together, it will create great synergy. For this synergy, Formosa Group plans to actively invest in related Korean companies," Sandy Wang, chairman of Taiwan's Formosa Group, said in a recent written interview with [South Korea’s] Maeil Business. Chairman Wang said, "The partnership with Korea is to overcome the limitations of information and communication technology (ICT) and Taiwan's semiconductor-oriented industry to gain new industry growth and power." More... |
| Lumosa Therapeutics' LT3001 new drug clinical trial enrollment progressing well, unblinding by year-end planned 15 May, 2024 Lumosa Therapeutics' (TW: 6535) new General Manager, 'Yeh Sheng-wen, stated during a recent press conference that among the three key Phase II clinical trials of LT3001, the clinical trial in China, conducted by its partner Shanghai Pharmaceuticals, has progressed well. Currently, over 80 percent of the patient enrollment is completed, with the Last Patient In (LPI) expected by mid-year, with unblinding on track for the end of the year. Additionally, two multinational clinical trials led by Lumosa Therapeutics are also expected to be completed by 2025. More... (in Chinese) |
| TCM Biotech International attends health products exhibition Vitafoods Europe 2024 15 May, 2024 The annual event of the global nutrition and health industry, Vitafoods Europe 2024, kicked off in Geneva on the 14th. Over the three-day exhibition, TCM Biotech International (TW: 4169) showcased its research and development of its liver-protecting ingredient, LivPhcD, under the theme Best Solution For Liver Health, along with its proprietary brand of health foods. More... (in Chinese) |
| Taiwan nutra market: Eye health, beauty, probiotics trending, with food firms, influencers entering business 15 May, 2024 Eye care is consistently cited as one of the top trending health supplement categories in Taiwan, alongside beauty-from-within, and functional probiotics that serve purposes beyond gut health, say leading industry players in our latest deep dive into a key Asian market. More... |
| Taiwan's Adimmune Corp. signs benefit-sharing agreement with WHO 14 May, 2024 Taiwan-based vaccine maker Adimmune Corp. on Tuesday said it has signed an agreement with the World Health Organization (WHO) to receive early biological samples of emerging influenza variants. More... |
| AstraZeneca Improves Healthcare Through Collaboration and Community Sponsored interview 14 May, 2024 As an international biomedical and pharmaceutical leader, AstraZeneca's impact on the global healthcare landscape is undeniable. The company's pioneering efforts have been instrumental in safeguarding millions worldwide from severe illness and death. But exceeding expectations is something that is embedded in the company's culture, explains Vita Chien, general manager of AstraZeneca Taiwan since November 2023. "We recognize that every team member brings their own strengths to the role, and we encourage people to work as a team to unleash everyone's individual potential," she says. More... |
| PharmaEngine's Onivyde approved by the European Medicines Agency (EMA), launches in Germany 29 April, 2024 PharmaEngine (TW: 4162) announced that its international partner, Servier, had obtained approval from the European Medicines Agency (EMA) for a change in indication and dosage for Onivyde in the European Union. The new indication approved by the EMA is for the treatment of metastatic pancreatic cancer, in combination with oxaliplatin, 5-fluorouracil, and leucovorin, as a first-line treatment for patients. The company also announced that the drug would be launched in Germany. More... (in Chinese) |
| NHRI and collaborators establish Taiwan's first local cancer gene database 14 May, 2024 The National Health Research Institutes (NHRI) and Health and Welfare Ministry, along with five major pharmaceutical companies and 17 hospitals, have collaborated to establish Taiwan's first local cancer gene database. More... |
| TaiMed's TMB365/380 Core group II(a) clinical trial completes early enrollment 13 May, 2024 TaiMed Biologics (TW: 4147) announced that its TMB365/380 core group II(a) clinical trial has completed enrollment ahead of schedule. Data analysis is expected to be available from the end of 2024 to early 2025. The company plans to initiate licensing negotiations with major international pharmaceutical companies as they move into the II(b) clinical phase. The TMB365/380 core group II(a) clinical trial planned to include 20 participants. The enrollment of the first participant was announced in late March. By last Friday (May 10), all participants had been enrolled. Excluding weekends, Easter, and other US holidays, it took just over 40 working days to complete the enrollment for the II(a) phase, significantly ahead of schedule. More... (in Chinese) |
| Bio Preventive Medicine's IVD reagent DNlite-IVD103 approved in Indonesia 13 May, 2024 Bio Preventive Medicine (TW: 6810) recently announced that its independently-developed IVD testing reagent, DNlite-IVD103, has been granted market approval by the Ministry of Health (MOH) of Indonesia. It is indicated for predicting the risk of diabetic kidney disease (DKD) in Type 2 diabetes patients, becoming Taiwan's first innovative biomarker IVD product to enter the Indonesian market, according to the announcement. More... (in Chinese) |
| Formosa Pharmaceuticals' new ophthalmic drug licensed to Saudi Arabia's largest private pharmaceutical company 10 May, 2024 Formosa Pharmaceuticals (TW: 6838) announced that on April 30th it signed a licensing agreement with Saudi pharmaceutical company Tabuk Pharmaceuticals. Under this agreement, Tabuk Pharmaceuticals has obtained the exclusive rights to commercialize and sell APP13007 (Clobetasol Propionate Nanoparticle Ophthalmic Suspension 0.05%), a patented new drug developed by Formosa Pharmaceuticals for treating inflammation and pain following eye surgery, in key markets in the Middle East and North Africa regions. More... (in Chinese) |
| National Chung Cheng University Develops Rapid Biosensor, detects sepsis in minutes with just one drop of blood 10 May, 2024 A team at Taiwan's National Chung Cheng University has developed a Sepsis Rapid Screening Platform. The system's rapid biosensor utilizes innovative nano-gold particles and optical waveguide biosensor technology, requiring only about one drop of blood sample to produce results, according to an announcement. The sensor's sensitivity breaks records, reducing detection time from the original 15 minutes to only eight minutes, facilitating faster and more accurate diagnosis of sepsis. More... (in Chinese) |
| AmCad BioMed in talks with EchoNous to develop new markets for handheld ultrasound devices 9 May, 2024 AmCad BioMed (TW: 4188), a developer of innovative ultrasound imaging medical devices, has recently completed hardware and software integration to develop a handheld ultrasound (POCUS, Point-of-Care Ultrasound) device. The company has signed a non-disclosure agreement (NDA) with the leading US handheld ultrasound company EchoNous and is in further discussions for cooperation to jointly explore new markets for POCUS ultrasound devices. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2024 (24-28 July, 2024) ========================================= Taiwan Bio Industry Organization (TBIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |